Which FLT3 Inhibitor for Treatment of AML?

doi:10.1007/s11864-022-00952-6

Back to search

Article

Which FLT3 Inhibitor for Treatment of AML?

Current treatment options in oncology - 1 Mar 2022

Senapati Jayastu, Kadia Tapan Mahendra

Abstract excerpt

OPINION STATEMENT: Treatment options in acute myeloid leukemia (AML) have improved significantly over the last decade with better understanding of disease biology and availability of a multitude of targeted therapies. The use of FLT3 inhibitors (FLT3i) in FLT3-mutated (FLT3mut) AML is one such de...

Topics

Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Transplantation, Homologous
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.